Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme

HealthTech approach

HealthTech approach

Advice programme

Area of interest

Showing 101 to 125 of 2563

TitleReference numberPublishedLast updated
Suspected sepsis in over 16sQS213
Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone‑sensitive metastatic prostate cancerTA1110
Nintedanib for treating fibrosing interstitial lung disease in people 6 to 17 years (terminated appraisal)TA1111
Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (terminated appraisal)TA1112
Suspected sepsis in people aged 16 or over: recognition, assessment and early managementNG253
Suspected sepsis in under 16s: recognition, diagnosis and early managementNG254
Suspected sepsis in pregnant or recently pregnant people: recognition, diagnosis and early managementNG255
Low-energy contact X-ray brachytherapy for rectal cancerHTG763
Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancerTA1109
Cabotegravir for preventing HIV-1 in adults and young peopleTA1106
Delgocitinib for treating moderate to severe chronic hand eczemaTA1107
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancerTA1108
Iptacopan for treating complement 3 glomerulopathy (terminated appraisal)TA1102
VA ECMO for severe acute heart failure in adultsHTG764
VA ECMO for extracorporeal cardiopulmonary resuscitation (ECPR) in adults with refractory cardiac arrestHTG765
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal)TA1104
Clascoterone for treating acne vulgaris in people 12 years and over (terminated appraisal)TA1105
Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitorTA1103
Head injuryQS74
Rehabilitation for chronic neurological disorders including acquired brain injuryNG252
Artificial intelligence (AI) technologies to aid opportunistic detection of vertebral fragility fractures: early value assessmentHTG760
Sparsentan for treating primary IgA nephropathyTA1074
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and overTA1101
Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapyTA1099
Mirabegron for treating neurogenic detrusor overactivity in people 3 to 17 years (terminated appraisal)TA1100

Results per page

  1. 10
  2. 25
  3. 50
  4. All